Zomedica (ZOMDF) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
There is no meaningful price-target consensus for Zomedica (ZOMDF): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. No analyst publishes estimates on it either. What is left is the latest reported figures, the drivers and the risks below, which you assess yourself. Walnut is not an investment adviser.
Why ZOMDF has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. ZOMDF is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.
Trailing revenue is derived from ~$32.0 million in 2025 plus ~$28.2 million in the first nine months of 2026, less ~$21.6 million in the first nine months of 2025. At ~$0.08 a share, the market value of ~$80 million is about ~2.1 times sales and below book value (Yahoo shows ~0.77 times book). Subtracting ~$40.9 million of liquidity leaves an enterprise value near ~$39 million, about ~1.0 times sales. Because the company is unprofitable, earnings-based multiples do not apply.
ZOMDF: the latest reported figures
No analyst publishes estimates on ZOMDF, so these are the most recent figures we hold, as of November 2026. They describe where the company stands, not where it is going.
- Revenue (TTM): ~$38.7 million; Q3 2026 ~$9.9 million, up ~22%
- Net loss (TTM): ~$16 million; Q3 2026 ~$3.2 million (vs ~$6.1 million)
- Gross margin (Q3 2026): ~61%
- Market cap: ~$80 million (~$0.08 a share, Nov 20, 2026)
- Price / sales: ~2.1x
- Cash + securities (Sep 30, 2026): ~$40.9 million
- Shares outstanding: ~980 million
Is there a 2030 forecast for ZOMDF?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering ZOMDF do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Zomedica can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move ZOMDF from here
In short: the drivers cited most often are PulseVet consumables and the installed base, TRUFORMA diagnostics and the Boehringer collaboration, Development Services as a new revenue line. The risk cited most often against it is the plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ZOMDF is it a buy page.
Your questions about Zomedica
Ask Walnut's AI anything about ZOMDF and see how it fits what you own.
FAQ
What is the price target for Zomedica (ZOMDF)?
+
There is no meaningful consensus price target for ZOMDF, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does ZOMDF have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean the analysis starts with you, because there is no published model to build on.
What could move ZOMDF?
+
The drivers and the risks are laid out on this page and in more depth on the ZOMDF "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.